#### VIA FIRST\_CLASS MAIL

I hereby certify that this corresponde States Postal Service as first class m. Patent and Trademark Office on Janua

being deposited with the United a envelope addressed to the U.S.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

GURE et al.

Serial No

09/975,856

Filed

October 11, 2001

For

ANTIBODIES SPECIFIC FOR SSX PROTEINS

Art Unit

UNKNOWN

Examiner

**UNKNOWN** 

January 8, 2002

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

### LETTER-RESPONSE TO SEQUENCE REQUIREMENT

In response to the "Notice To Comply" which issued on December 28, 2001, a copy of which is attached, applicants note that the subject application is a divisional of 09/796,780, and they expressly filed a proper sequence transfer letter on October 10, 2001, a copy of which is attached.

Hence, the Notice issued incorrectly, and withdrawal thereof is appropriate.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

Norman D. Hanson, Esq. Registration No. 30,946

666 Fifth Avenue

New York, New York 10103-3198

Telephone: 212-318-3168 Telecopier: 212-318-3400



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
MASH-MOTON, D.C. 20.20
WWW.USDIC.GON

APPLICATION NUMBER

FILING RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/975,856

10/11/2001

Ali O. Gure

LUD-5480.2 DIV

Fulbright & Jaworski LLP 666 Fifth Avenue New York, NY 10103



CONFIRMATION NO. 2513
FORMALITIES LETTER
\*OC000000007239772\*

Date Mailed: 12/28/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

## For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE